Despite the wide diversity in structure and composition, the HMO found in human milk are structurally distinct. While some oligosaccharides are universal, only 3'-SL is present in all animal milks, suggesting that this molecule has universal functions. Ultimately, these oligosaccharides are important for postnatal development.
Market Statistics:
The global human milk oligosaccharides market is estimated to account for US$ 152.41 Mn in terms of value by the end of 2021.
Global Human Milk Oligosaccharides Market: Drivers
Growing demand for HMO fortified infant formulas and supplements is driving growth of the human milk oligosaccharides market. For instance, in November 2021, Abbott Nutrition introduced Similac Pro-Advance® with 2'-Fucosyllactose Oligosaccharide† (2'-FL†), which claimed to be the first product in Canada with HMO ingredient in infant formula. Similac formula with 2'-FLis an ingredient identical in structure to 2'-FL HMO, an immune component found in breast milk.
Global Human Milk Oligosaccharides Market: Opportunities
Increasing investment by key players in human milk oligosaccharides products is projected to bring bright market opportunities. For instance, in November 2021, Asia's cell-based food sector, Turtle Tree, had raised the investment for USD 30 million for introducing human milk oligosaccharides (HMOs), which can be used as blends in sports nutrition and infant formula, as well as dairy products like cheese and yogurt and further to scale up its production in the United States and Singapore.
Global Human Milk Oligosaccharides Market: Restraints
High cost of production is expected to hinder the growth of the human milk oligosaccharides market
Global Human Milk Oligosaccharides Market - Impact of Coronavirus (Covid-19) Pandemic
COVID-19 was incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Although the COVID-19 pandemic is still transforming the growth of numerous industries, the outbreak's immediate impact was varied. While some sectors may experience a decline in demand, many others continue to stay unaffected and exhibit strong development prospects.
To know the latest trends and insights prevalent in the Global Human Milk Oligosaccharides Market, click the link below:
https://www.coherentmarketinsights.com/market-insight/human-milk-oligosaccharides-market-5064
Key Takeaways:
The global human milk oligosaccharides market was valued at US$ 152.41 Mn in 2021 and is forecast to reach a value of US$ 612.0 Mn by 2030 at a CAGR of 19.65% between 2022 and 2030.
Functional Food and Beverage segment held second highest market in the global Human Milk Oligosaccharides market in 2021, and is expected to grow at a CAGR of 19.65% during forecast period, increasing approval and launch of new products is expected to propel growth of the segment during the forecast period.
Market Trends:
Increasing biosynthetic production of HMOs for dietary supplements is expected to be a major trend in the market. Growing application in functional food &beverages is again projected to augment market growth. Moreover, rapid technological advancement in the product line and also in diary industry is further projected to foster market growth.
Global Human Milk Oligosaccharides Market: Competitive Landscape
ZuChem Inc., Merck & Co. Inc., Chr. Hansen Holding AS (Jennewein Biotechnologie GmbH), Royal FrieslandCampina NV, BASF, IFF (DuPont Nutrition & Health), Gnubiotics, Inbiose NV, Carbosynth Holdings Limited, and Royal DSM N.V
Global Human Milk Oligosaccharides Market: Recent Developments
- In February 2021, International Flavors &Fragrances announced the merger of DuPont’s Nutrition & Biosciences business with a one-time cash payment of USD 7.3 billion; this venture has created a global ingredients and solutions company that will serve consumer-oriented food and beverage, as well as health and wellness end markets.
- In April 2019, Gnubiotics Sciences SA launched its first-in class microbiome modulating prebiotic GNU100 Gnubiotics’ which is registered in Europe as an oligosaccharide- peptide complex with the objective to enhance microbiota restoration. GNU100 comprises of at least 30 different oligosaccharide structures that are functional mimics of Human Milk Oligosaccharides (HMOs).
- In July 2021, Inbiose NV submitted its application for a Generally Recognized as Safe (GRAS) approval by the US Food & Drug Administration (FDA) of four human milk oligosaccharides (HMOs) including Lacto-N-Tetraose and Lacto-N- neoTetraose. Inbiose NV expects to obtain regulatory approval for these HMOs in 2022.
